Drug intelligence / Profile preview

qizao granules

Development stage: Unknown
Lead developer: Shaanxi Tianyang Pharmaceutical
Administration: Oral

Overview

Qizao Granules is a traditional Chinese medicine (TCM) developed and manufactured by Shaanxi Tianyang Pharmaceutical. The formulation is primarily composed of extracts from *Astragalus membranaceus* (Huangqi) and *Ziziphus jujuba* (Dazao). According to TCM principles, the drug functions to tonify Qi and nourish the blood. It is clinically indicated for the treatment of symptoms resulting from Qi and blood deficiency, including chronic fatigue, dizziness, palpitations, and insomnia. Furthermore, it is frequently utilized as a supportive therapy for leukopenia (low white blood cell count), particularly in patients undergoing chemotherapy or radiotherapy, due to its purported ability to stimulate hematopoietic function and modulate the immune response.

Brand names: 芪枣颗粒
Other names: Qizao KeliQizao Granules

Beyond the preview

Go deeper on qizao granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on qizao granules.

Explore the full profile